NTLA icon

Intellia Therapeutics

8.16 USD
-0.24
2.86%
Updated Mar 28, 12:37 PM EDT
1 day
-2.86%
5 days
-11.40%
1 month
-19.13%
3 months
-28.48%
6 months
-60.29%
Year to date
-33.22%
1 year
-70.34%
5 years
-35.65%
10 years
-63.08%
 

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

91% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 66

43% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $11.5M

33% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 49

5.09% more ownership

Funds ownership: 92.39% [Q3] → 97.47% (+5.09%) [Q4]

4% more funds holding

Funds holding: 280 [Q3] → 291 (+11) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

39% less capital invested

Capital invested by funds: $1.93B [Q3] → $1.17B (-$758M) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
35%
upside
Avg. target
$33
306%
upside
High target
$68
733%
upside

11 analyst ratings

positive
64%
neutral
36%
negative
0%
HC Wainwright & Co.
Mitchell Kapoor
33% 1-year accuracy
60 / 182 met price target
268%upside
$30
Buy
Initiated
5 Mar 2025
Truist Securities
Joon Lee
55% 1-year accuracy
22 / 40 met price target
513%upside
$50
Buy
Maintained
4 Mar 2025
Barclays
Gena Wang
24% 1-year accuracy
7 / 29 met price target
219%upside
$26
Overweight
Maintained
28 Feb 2025
Citigroup
David Lebowitz
42% 1-year accuracy
8 / 19 met price target
72%upside
$14
Neutral
Maintained
28 Feb 2025
Wells Fargo
Yanan Zhu
0% 1-year accuracy
0 / 16 met price target
513%upside
$50
Overweight
Maintained
28 Feb 2025

Financial journalist opinion

Based on 273 articles about NTLA published over the past 30 days

Neutral
Accesswire
2 hours ago
Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139477&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Neutral
Accesswire
2 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Neutral
Accesswire
5 hours ago
NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139372&wire=1 or contact Joseph E. Levi, Esq.
NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Neutral
Accesswire
5 hours ago
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Neutral
Seeking Alpha
6 hours ago
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
Intellia received RMAT designation from the FDA of nex-z for the treatment of patients with Transthyretin [ATTR] Amyloidosis with Cardiomyopathy. Global sales of the Transthyretin Amyloidosis market is expected to reach $12 billion by 2028. Long-term data from the phase 1/2 study, using NTLA-2002 for the treatment of patients with Hereditary Angioedema, expected in 2025.
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
Neutral
PRNewsWire
6 hours ago
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
NEW YORK , March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025.
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
Neutral
Accesswire
16 hours ago
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NTLA
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139321&wire=1 or contact Joseph E. Levi, Esq.
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NTLA
Neutral
GlobeNewsWire
16 hours ago
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.
Neutral
Accesswire
17 hours ago
Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139308&wire=1 or contact Joseph E. Levi, Esq.
Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Neutral
Accesswire
18 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Charts implemented using Lightweight Charts™